Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction
NCT ID: NCT02754219
Last Updated: 2018-02-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
24 participants
INTERVENTIONAL
2016-09-22
2018-01-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function
NCT02170571
Effect of Hepatic Impairment on LDE225..
NCT01764776
A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants
NCT04960124
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
NCT04643795
GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers
NCT05814926
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Evogliptin
Hepatic dysfunction, Healthy control
Evogliptin
DPP4-inhibitor, Evogliptin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Evogliptin
DPP4-inhibitor, Evogliptin
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 6 months with chronic liver disease (Regardless of cause hepatic dysfunction)
* Child-Pugh A or B
\<Healthy Control\>
* Subject has the following conditions: age ± 5 years, BMI ± 20%, same sex of each matched hepatic dysfunction subject
Exclusion Criteria
* Child-Pugh C
* History of Liver transplant
\<Healthy Control\>
* History of chronic liver disorders
* Pregnant or lactating women
19 Years
64 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dong-A ST Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Severance Hospital Clinical Trial Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DA1229_HI_I
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.